Kyowa Hakko President Yuzuru Matsuda : Speed is Key in Growing Globally
This article was originally published in PharmAsia News
Executive Summary
In an interview with Yakuji News, Kyowa Hakko President Yuzuru Matsuda said the company was moving faster to compete globally and achieve market leadership in antibody drugs. The antibody drug market reached ¥2,200 billion last year and is estimated to reach ¥4,500 billion by 2011. A merger with Kirin Pharma is expected to create synergy for the two companies that combine Kyowa's Potelligent technology and Kirin's KM mouse technology for creating humanized antibodies. This will boost efficiency in R&D and speed up new drug development, which Matsuda said was key for Kyowa. The company has three drugs in clinical trials: Kyowa's CCR4 antibody-KW-076, Medimmune's receptor antibody-BIW-8405, and Medarex's CD 30 antibody-MDX-1401. (Click for more-Japanese language